Retatrutide, a new dual agonist of the GLP-1 binding site and glucose-dependent insulinotropic polypeptide (GIP) binding site , is exhibiting promising results in preliminary clinical trials . Current https://bookmarkbells.com/story21434677/retatrutide-emerging-investigations-and-potential-medical-uses